Comparable Outcomes for Hematologic Malignancies after HLA-Haploidentical Transplantation with Posttransplantation Cyclophosphamide and HLA-Matched Transplantation
The implementation of high-dose posttransplantation cyclophosphamide (PTCy) has made HLA-haploidentical (haplo) blood or marrow transplantation (BMT) a cost effective and safe alternative donor transplantation technique, resulting in its increasing utilization over the last decade. We review the ava...
Main Authors: | Shannon R. McCurdy, Ephraim J. Fuchs |
---|---|
Format: | Article |
Language: | English |
Published: |
Hindawi Limited
2015-01-01
|
Series: | Advances in Hematology |
Online Access: | http://dx.doi.org/10.1155/2015/431923 |
Similar Items
-
Nonmyeloablative, HLA-haploidentical bone marrow transplantation with high dose, post-transplantation cyclophosphamide
by: Ashley Munchel, et al.
Published: (2011-06-01) -
Post-transplantation Cyclophosphamide: From HLA-Haploidentical to Matched-Related and Matched-Unrelated Donor Blood and Marrow Transplantation
by: Louis Williams, et al.
Published: (2020-04-01) -
Haploidentical stem cell transplants with Post transplantation cyclophosphamide for Hematological malignancies in children
by: Neha Rastogi, et al.
Published: (2016-01-01) -
A Review of Cyclophosphamide-Induced Transplantation Tolerance in Mice and Its Relationship With the HLA-Haploidentical Bone Marrow Transplantation/Post-Transplantation Cyclophosphamide Platform
by: Hisanori Mayumi
Published: (2021-09-01) -
The Immunobiology of HLA-Haploidentical Hematopoietic Cell Transplantation
Published: (2020)